Jonni Moore President-Elect Candidate Statement
To be nominated for president-elect of ISAC is truly an honor and an opportunity. If elected, I will approach the presidency with energy and passion to work with Council, society leaders and our executive director to assure ISAC’s continued leadership in cytometry. Now more than ever, the technologies of imaging and flow cytometry and associated computational technologies, are critical to advancing basic and clinical and translational science. As this landscape continues to evolve, ISAC must also evolve and work diligently to address multiple issues to assure our continued relevance and maintain our leadership. I will work diligently with the leaders in our field, both scientific and industrial to assure we take our place in the innovative, technology-rich future of biotechnology. To achieve this, we must be acutely aware of the broadening of the constituency of ISAC to include not only the engineers and clinical and research scientists, but also the educators, innovators, and shared resource scientists, as well as our colleagues in industry settings. Only these combined interactions will lead to a secure future for both ISAC and our technology. My career spans over 30 years of experience, encompassing all these constituencies, and I will work diligently to integrate the contributions and needs of each constituency to enhance the presence of ISAC in the community and the world of science and technology.
My presidency would build on the creativity and effort of those preceding me. I will be guided by 3 keywords: Education, Innovation, Collaboration
. Each one of our constituencies are crucial to success in these areas. As a lifelong educator, I am acutely aware of the power of knowledge. ISAC, and CytoU should be the undisputed leader in technology education as well as operational education (SRL) for the field of cytometry. I will seek to leverage the outstanding educational resources that exist within our membership and with our industry colleagues, as well as new offerings from CytoU, to rapidly push forward this objective. Much of the content exists and the effort would focus on processes to deliver through CytoUniversity as the portal. Education also embraces mentoring, and I would support the development of mentoring/educational activities at the college and even high school level to increase interest in the STEM areas, perhaps by developing a speaker's bureau. As an academic entrepreneur and lifelong laboratory innovator, I know the value of encouraging out-of-the box thinking and supporting innovation on multiple levels. I strongly support the establishment of an Innovation Scholars Program, working with foundations and our industrial partners, that can support young entrepreneurial scientists to bring new ideas and developments to the field. Collaboration may be the most important of the keywords and includes internal as well as external opportunities. SRLs are central to this as they are the interface with the scientific and biotech community. Through education and collaboration, the reach of cytometry will continue to expand. I have seen this in my own SRL where we constantly have projects underway with “non-traditional” flow cytometry areas in both application and instrument development. From a society perspective, collaboration with other professional societies will be key to embracing our future path. I will be an advocate to medical specialty societies, cell therapy societies, immunology societies, among others around the world to explore active interactions that will be mutually beneficial.
My history with ISAC and other regional, national, and international flow cytometry organizations is over 25 years long. I have attended almost every ISAC/CYTO meeting over the past 25 years, and have always presented an abstract, frequently chaired sessions or given platform presentations. As president, I will work to constantly re-evaluate the format of the meeting to keep it relevant in today’s digital world. I have continuously supported the society in many roles, including participation in the Resource Managers Task Force (predecessor of the SRL Committee), the Education Task Force that I chaired (predecessor to the Education Committee of which I remain a member), and now as leader of the Flow Cytometry Content Taskforce of CytoU University. I also serve on the SRL Emerging Leaders Committee and the Innovation Committee. I have been an invited participant in the ISAC Strategic Planning Retreats both in 2014 and 2017 as well as the Education Retreat. I am a founding member of both ICCS (served on Corporate Relations Committee, co-founder of the ICCS Women in Cytometry Group) and GLIIFCA (member of GLIIFCA Steering Committee for 15 years, twice President), and frequent attendee at both MetroFlow and Chesapeake Cytometry Consortium.
: I received my Ph.D. in Microbiology and Immunology from Jefferson University in Philadelphia, joined the Department of Pathology and Laboratory Medicine at the University of Pennsylvania as a postdoctoral fellow, and was subsequently appointed to the faculty, where I remain, rising to the rank of full professor. I have served as Faculty Director of the Abramson Cancer Center Flow Cytometry and Cell Sorting Shared Resource, a facility that has received the NIH’s highest rating of outstanding/exceptional for 30 years. My expertise in SRL management extends beyond flow cytometry as I am also Executive Director of Path BioResource at Penn, a consortium of 8 shared resource labs. I founded the Clinical Flow Cytometry Laboratory of the Hospital of the University of Pennsylvania where I was Director for 20 years and remain as senior advisor. I have more than 30 years’ experience in laboratory medicine and research in cellular immunology and have done novel work in deep phenotyping by flow cytometry and evaluation of extracellular vesicles in translational and clinical settings. More recently my research has evolved along the path of technology development with a focus on complex technologies, in particular on combining cytometry with systems biology. I have authored over 100 peer-reviewed publications, served as PI on several NIH grants, and hold several patents. I have spoken at various local and national symposia on topics ranging from new vistas for clinical cytometry, new technology and applications in the translation space, operational and organizational issues for SRLs, and consulted for the NIH on the topic of Shared Resource Labs. The SRL I direct, which serves over 1000 laboratories, is a noted model for its extensive educational programs and for the development of a unique career path for resource scientists. I have been honored to receive several awards and give honorary lectures including Penn’s prestigious Award for the Advancement of Women in Medicine, Carlton and Sigrid Stewart Award of GLIIFCA, the Keynote Speaker at the 2012 Annual Course in Cytometry held in Bowdoin, ME (where I have also lectured in 2015 and 2018), and the inaugural speaker for the ICCS Coulter Foundation Women in Cytometry symposium in 2011. In 2016, I received the Wallace H. Coulter Distinguished Lecturer Award for lifetime contributions to the science, education and practice of Clinical Cytometry.
Most recently, I have taken on the role of academic entrepreneur as co-founder of CytoVas, LLC, a cardiovascular diagnostics company founded through the Pennovation Program of the Center for Technology Transfer at the University of Pennsylvania. CytoVas has developed a flow cytometry based cardiovascular diagnostic, the Vascular Health Profile, which uses precision cytomics to evaluate the health of a patient’s vascular system. This is the first-in-sector clinical flow cytometry test for cardiovascular disease.